Pfizer to acquire US commercialization rights of Synthon’s glatiramer acetate to treat RRMS
In November 2011, Synthon filed an abbreviated new drug application (ANDA) with the US Food and Drug Administration (FDA) for a once daily 20mg/ml formulation of glatiramer acetate,
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.